Literature DB >> 17624760

The insulin-like growth factor 1 receptor in cancer: old focus, new future.

Hermien Hartog1, Jelle Wesseling, H Marike Boezen, Winette T A van der Graaf.   

Abstract

The importance of insulin-like growth factor 1 receptor (IGF-1R) signalling in malignant behaviour of tumour cells is well established. Currently, development of drugs targeting the IGF-1R as anticancer treatment is emerging. Several IGF-1R targeting strategies are being investigated in phases I and II clinical trials. Interactions of IGF-1R with insulin receptor, however, might complicate efficiency and tolerability of such drugs. This review describes mechanisms, recent developments and potential limitations of IGF-1R antibodies and tyrosine kinase inhibitors.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17624760     DOI： 10.1016/j.ejca.2007.05.021

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  53 in total

Review 1.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

2.  Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies.

Authors:  Amit Mahipal; Dave Shibata; Erin Siegel; Gregory Springett; Khaldoun Almhanna; William Fulp; Irene Williams-Elson; Richard Kim
Journal:  Invest New Drugs       Date:  2015-08-16       Impact factor: 3.850

Review 3.  Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.

Authors:  Pushpendra Singh; Jimi Marin Alex; Felix Bast
Journal:  Med Oncol       Date:  2013-12-14       Impact factor: 3.064

Review 4.  Signal transduction in transgenic mouse models of human breast cancer--implications for human breast cancer.

Authors:  Richard Marcotte; William J Muller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-07-24       Impact factor: 2.673

5.  Type I insulin-like growth factor receptor induces pulmonary tumorigenesis.

Authors:  Nicolle M Linnerth; Megan D Siwicky; Craig I Campbell; Katrina L M Watson; James J Petrik; Jeffrey A Whitsett; Roger A Moorehead
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

6.  miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor.

Authors:  Jinling Guo; Bairong Xia; Fanling Meng; Ge Lou
Journal:  Tumour Biol       Date:  2013-10-15

7.  Igf1r as a therapeutic target in a mouse model of basal-like breast cancer.

Authors:  Apostolos Klinakis; Matthias Szabolcs; Guoying Chen; Shouhong Xuan; Hanina Hibshoosh; Argiris Efstratiadis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

8.  Quantitative proteome profiling of lymph node-positive vs. -negative colorectal carcinomas pinpoints MX1 as a marker for lymph node metastasis.

Authors:  Roland S Croner; Michael Stürzl; Tilman T Rau; Gergana Metodieva; Carol I Geppert; Elisabeth Naschberger; Berthold Lausen; Metodi V Metodiev
Journal:  Int J Cancer       Date:  2014-05-12       Impact factor: 7.396

9.  IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients.

Authors:  Michal Rajski; Rosanna Zanetti-Dällenbach; Brigitte Vogel; Richard Herrmann; Christoph Rochlitz; Martin Buess
Journal:  BMC Med       Date:  2010-01-05       Impact factor: 8.775

10.  Persistent transcription-blocking DNA lesions trigger somatic growth attenuation associated with longevity.

Authors:  George A Garinis; Lieneke M Uittenboogaard; Heike Stachelscheid; Maria Fousteri; Wilfred van Ijcken; Timo M Breit; Harry van Steeg; Leon H F Mullenders; Gijsbertus T J van der Horst; Jens C Brüning; Carien M Niessen; Jan H J Hoeijmakers; Björn Schumacher
Journal:  Nat Cell Biol       Date:  2009-04-12       Impact factor: 28.824
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.